Please ensure Javascript is enabled for purposes of website accessibility

69% of Chronic Disease Patients Are Struggling to Cope During Coronavirus Outbreak, Survey Finds

By Eric Volkman – Apr 20, 2020 at 10:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Inability to access health care or pay for medications are among their acute concerns.

The strain that the SARS-CoV-2 coronavirus outbreak is putting on the healthcare system is having a strongly negative impact on people who suffer from chronic diseases. That's the stark finding of a new survey conducted by market research company InCrowd with patients that are coping with such ailments.

According to the survey's results cited by FierceHealthcare, 69% of respondents said that they are currently having at least some difficulty managing their conditions. The survey comprised patients with seven types of conditions -- cancer, multiple sclerosis, high blood pressure, asthma, migraines, diabetes, and autoimmune diseases.

Man at a table with bottles of pills.

Image source: Getty Images.

One key issue cited was access to healthcare, given the level of resources and the number of professionals being deployed in the fight against COVID-19. Some respondents said they were unable to see doctors or secure appointments for needed procedures.

Another problem was the affordability of medications, since many companies are either laying off or furloughing their employees. People now out of work who also have chronic conditions worry that they won't be able to afford the medications they need; some report that they are "stretching" their current supply.

Broadly speaking, 70% of the survey's respondents said they were more concerned about the state of their health than they were at "normal" times, and almost one in three said they were afraid to leave their homes to receive medical treatment.

Such conditions would understandably favor the growth of remote-medicine services such as Teladoc Health (TDOC -3.35%), which has seen its profile rise significantly amid the ongoing coronavirus stay-at-home mandates. Teladoc is a high-profile company in its segment.

That said, Friday wasn't a good day for Teladoc shares; they fell 0.5% on the day, in contrast to the 2.7% gain posted by the broader market as measured by the S&P 500 index.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$25.35 (-3.35%) $0.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.